Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection.
about
Should we treat acute HIV infection?Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruptionResisting immune exhaustion in HIV-1 infection.Modelling HIV immune response and validation with clinical data.The detection and management of early HIV infection: a clinical and public health emergency.Dynamics of viral evolution and CTL responses in HIV-1 infectionGene expression before HAART initiation predicts HIV-infected individuals at risk of poor CD4+ T-cell recoveryHow HIV treatment could result in effective preventionNo treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial.Immunological and virological benefits resulted from short-course treatment during primary HIV infection: a meta-analysisCD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway.The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.A Randomized Trial of Time-Limited Antiretroviral Therapy in Acute/Early HIV Infection.Using mathematical modeling and control to develop structured treatment interruption strategies for HIV infection.Administration of Fozivudine tidoxil as a single-agent therapeutic during acute feline immunodeficiency virus infection does not alter chronic infectionAre there benefits to starting antiretroviral therapy during primary HIV infection? Conclusions from the Seattle Primary Infection Cohort vary by control groupReduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxisEfficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.Higher homologous and lower cross-reactive Gag-specific T-cell responses in human immunodeficiency virus type 2 (HIV-2) than in HIV-1 infectionAcute HIV infection: the impact of anti-retroviral treatment on cellular immune responses.HIV rebounds from latently infected cells, rather than from continuing low-level replicationImmunophenotypic alterations in acute and early HIV infectionClinical management of acute HIV infection: best practice remains unknown.A cure for AIDS: a matter of timing?Update on antiretroviral treatment during primary HIV infection.High Number of Activated CD8+ T Cells Targeting HIV Antigens Are Present in Cerebrospinal Fluid in Acute HIV Infection.Unusual primary HIV infection with colonic ulcer complicated by hemorrhagic shock: a case report.Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infectionHologram quantitative structure activity relationship, docking, and molecular dynamics studies of inhibitors for CXCR4.Epidemiologically linked transmission of HIV-1 illustrates the impact of host genetics on virological outcomeInterleukin-12 is the optimum cytokine to expand human Th17 cells in vitro.Lipodystrophy among HIV-Infected Patients Attending Care and Treatment Clinics in Dar es Salaam.A study on the dynamics of temporary HIV treatment to assess the controversial outcomes of clinical trials: An in-silico approach
P2860
Q26826523-A547060F-FC76-4E6B-96DD-317211045608Q28742727-993C0160-C6ED-4378-945A-46FC5AEB1E76Q33332291-DAEE05C0-4549-4C7A-B208-8A5B3893B6FCQ33460449-1119E82E-07B2-4A22-A071-599E0D6526E7Q33586581-289CE37C-704F-48F3-BDA2-1C895B884D11Q33809426-79DF4017-011C-46CE-AF86-A010E2D22293Q34043159-9452DC51-E9B3-415F-8502-B9B11EB50FE0Q34090397-23B9D647-E635-48F4-AE6B-A65770E97EA3Q34220902-A367A9A7-794E-4DAC-9752-4D3F3455B4C5Q35064203-8E0B6D47-CDDD-4D63-B5A9-A6C243CFDA57Q35115062-DEE9E3A3-51B5-4878-A2C7-E43BC2AD60F8Q35623734-5CC61395-5721-4262-A5FE-F4B15A05431EQ35850919-A68663A9-4884-44D1-9546-7636E32FCE9AQ36026242-4E16A71C-CD06-48D6-90FB-E539D925063DQ36096407-FF22A252-67B9-4596-8422-EC8008CF53BDQ36136406-82367734-8EBC-4F42-80FC-5E8BD7926E03Q36379277-030D15C1-E4B0-41E7-8A95-CE54D1AA68C3Q36601614-C97E6175-2150-4526-BEBB-72F80FC8CDE4Q36845911-A663EA78-9831-4083-8495-F8C920236A0CQ36859219-3B7C2440-B16C-4ECA-B4E9-6B27AD134ECDQ36954950-FF5289B8-529F-4623-BF5D-8B4A1FD0709AQ37243692-6FA0BEA6-EDD8-4D2F-B5B7-CD8D49F64928Q37789343-BBB654E3-C61F-4DA3-9CC1-B96C16C96651Q38165451-0FDE209B-5561-48D6-82AB-977FF61384DBQ38209874-46816305-3710-4041-A606-8618A5FF9167Q38433342-510AEF9D-36D3-4D55-918F-89E21A6106DEQ40350717-168AAA4A-4F12-4802-9DAE-4F4E652FC8C6Q41857492-097B0F83-E33E-433D-B4FF-9D0EA9285B63Q42212856-980D92B0-CD81-455E-BA69-3F0073771B6BQ42722482-B535D982-6091-44D3-AB46-DC3A82BA353DQ43117830-EC8F1730-A97B-4123-AB53-B87878A6106BQ43923867-FE9F4973-0B5F-4273-AF12-A0906CD9EC39Q57175535-9637CAD5-D076-4B25-91E8-0FD07C8C92EC
P2860
Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Immunological and virological ...... during acute HIV-1 infection.
@en
Immunological and virological ...... during acute HIV-1 infection.
@nl
type
label
Immunological and virological ...... during acute HIV-1 infection.
@en
Immunological and virological ...... during acute HIV-1 infection.
@nl
prefLabel
Immunological and virological ...... during acute HIV-1 infection.
@en
Immunological and virological ...... during acute HIV-1 infection.
@nl
P2093
P50
P356
P1476
Immunological and virological ...... during acute HIV-1 infection.
@en
P2093
Arne Jessen
Galit Alter
Heiko Jessen
Ingrid Stahmer
Juergen K Rockstroh
Mary Carrington
Mathias Lichterfeld
Mike T Waring
Nickolas Teigen
Xiaojiang Gao
P304
P356
10.1086/503811
P407
P577
2006-08-15T00:00:00Z